hVIVO plc (AIM:HVO) (Euronext Growth:HVO), a specialist contract research organisation (CRO), announced on Tuesday that it has secured a contract worth GBP11.5m with an undisclosed top-tier pharmaceutical company to test an antiviral candidate using its Respiratory Syncytial Virus (RSV) Human Challenge Study Model.

The Phase 2a trial will evaluate safety, pharmacokinetics and antiviral activity, leveraging hVIVO's FluCamp volunteer recruitment arm and state-of-the-art facilities.

This repeat contract underscores the value of hVIVO's human challenge trials in accelerating drug development, the company said. RSV remains a significant global health burden, and hVIVO's model has been instrumental in advancing RSV drug and vaccine candidates.

hVIVO reaffirmed its FY 2024 revenue guidance of GBP62m, with full-year EBITDA margins at the upper end of market expectations.

(USD1=GBP0.78)